Glaxo Pays $40 Million in (Another) Paxil Settlement

The settlement is the latest in a string of problems for Glaxo. At issue is whether the drugmaker promoted the antidepressant for unapproved use in children and adolescents, and whether it promptly shared information about possible risks.